Prescription Drugs: Shortages

There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply. Where supply issues do arise, we know how frustrating and distressing these can be for patients, and we work closely with industry, the National Health Service, and the Medicines and Healthcare products Regulatory Agency to resolve issues as quickly as possible, to make sure patients can access the medicines they need.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues.

While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise, to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, including pharmacists, so they can advise and support their patients.

The resilience of UK supply chains is a key priority, and we are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages, and to strengthen our resilience.